Endless Ark, an AI-driven anti-aging drug development company, has secured tens of millions of yuan in seed funding led by Monolith and followed by Jiuhui Venture Capital. The company aims to leverage its cross-species AI platform, H2P (Human-to-Pet), to identify conserved aging mechanisms between humans and pets, accelerating the development of both human and veterinary anti-aging drugs. Founded by Oxford PhDs in AI and aging research, Endless Ark's approach involves building a comprehensive database of pet aging data to inform and validate its AI models for drug discovery and development. AI
IMPACT This funding will accelerate the development of AI models for drug discovery, potentially leading to faster breakthroughs in both human and veterinary medicine.
RANK_REASON Significant funding round for an AI-driven biotech startup. [lever_c_demoted from significant: ic=1 ai=0.7]
- Endless Ark
- Jennifer Doudna
- Jiuhui Venture Capital
- MIT
- Monolith
- University of California, Berkeley
- Oxford University
- Zeng Jingkun
- Zhao Simiao
AI-generated summary · Google Gemini · from 1 sources. How we write summaries →
